기관지확장제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Bronchodilator Market size is expected to reach USD 40.86 Billion in 2034 from USD 28.91 Billion (2025) growing at a CAGR of 3.92% during 2026-2034.

The Global Bronchodilator Market is expanding steadily due to the rising prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary conditions. Increasing air pollution, smoking habits, and aging populations are contributing to higher incidence rates worldwide. Growing awareness about early diagnosis and treatment has also strengthened demand for effective bronchodilator therapies across hospitals, clinics, and homecare settings.

Key drivers include technological advancements in inhaler devices, improved drug formulations, and expanding healthcare access in developing countries. Pharmaceutical companies are focusing on combination therapies and long-acting bronchodilators to enhance patient compliance and treatment outcomes. Government initiatives aimed at improving respiratory healthcare infrastructure further support market expansion, especially in regions experiencing rapid urban growth.

In the future, the market is expected to grow with the development of personalized medicine and smart inhaler technologies that enable better disease management. Increasing research activities and strategic collaborations among pharmaceutical companies will likely introduce more efficient and targeted therapies. As respiratory health continues to be a global concern, the Global Bronchodilator Market is poised for sustained progress.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease

• Asthma
• COPD
• Others

By Route of Administration

• Inhalable
• Oral
• Injection

By Drug Class

• Beta-Adrenergics
• Anticholinergics
• Xanthine Derivatives
• Phosphodiesterase Inhibitors
• Combination Drugs

By Mode of Action

• Short Acting
• Long Acting

COMPANIES PROFILED

• AstraZeneca plc, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici SpA, Cipla Limited, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd, Merck Co Inc, Mylan NV now part of Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BRONCHODILATOR MARKET: BY DISEASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease
• 4.2. Asthma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. COPD Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BRONCHODILATOR MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Inhalable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BRONCHODILATOR MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Class
• 6.2. Beta-Adrenergics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Anticholinergics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Xanthine Derivatives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Phosphodiesterase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Combination Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BRONCHODILATOR MARKET: BY MODE OF ACTION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Mode Of Action
• 7.2. Short Acting Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Long Acting Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BRONCHODILATOR MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Disease
  • 8.2.2 By Route Of Administration
  • 8.2.3 By Drug Class
  • 8.2.4 By Mode Of Action
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Disease
  • 8.3.2 By Route Of Administration
  • 8.3.3 By Drug Class
  • 8.3.4 By Mode Of Action
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Disease
  • 8.4.2 By Route Of Administration
  • 8.4.3 By Drug Class
  • 8.4.4 By Mode Of Action
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Disease
  • 8.5.2 By Route Of Administration
  • 8.5.3 By Drug Class
  • 8.5.4 By Mode Of Action
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Disease
  • 8.6.2 By Route Of Administration
  • 8.6.3 By Drug Class
  • 8.6.4 By Mode Of Action
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BRONCHODILATOR INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AstraZeneca Plc
  • 10.2.2 Boehringer Ingelheim International GmbH
  • 10.2.3 Chiesi Farmaceutici S.P.A
  • 10.2.4 Cipla Limited
  • 10.2.5 GlaxoSmithKline Plc
  • 10.2.6 Glenmark Pharmaceuticals Ltd
  • 10.2.7 Merck & Co. Inc
  • 10.2.8 Mylan N.V. (Now Part Of Viatris Inc.)
  • 10.2.9 Novartis AG
  • 10.2.10 Sun Pharmaceutical Industries Ltd
  • 10.2.11 Teva Pharmaceutical Industries Ltd